Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERMAX vs FLEXERIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine D1/D2 receptor agonist; also activates α2-adrenergic and serotonin receptors, reducing prolactin secretion.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Parkinson's disease,Hyperprolactinemia
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
Initial: 0.05 mg orally once daily; titrate by 0.05-0.1 mg/day every 2-3 days; usual therapeutic dose: 0.1-0.5 mg three times daily; maximum: 1.5 mg three times daily.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Terminal elimination half-life: 27 hours (range 24-30 hours) in healthy adults; significantly prolonged in renal impairment (up to 100+ hours in ESRD), requiring dose adjustment.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Hepatic (CYP3A4, CYP1A2); extensive first-pass metabolism.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Renal: ~50% unchanged drug; biliary/fecal: ~40% as metabolites and parent drug; total clearance approximates hepatic blood flow.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
~90% bound to plasma proteins (primarily albumin).
~93% bound to plasma proteins, primarily albumin.
Vd: 6-8 L/kg (central compartment ~0.5 L/kg), indicating extensive tissue distribution.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Oral: ~50% (range 30-70%) due to first-pass hepatic metabolism; food does not significantly affect absorption.
Oral: ~33% due to extensive first-pass metabolism.
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
Child-Pugh Class A: use with caution, consider dose reduction; Child-Pugh Class B or C: contraindicated.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Safety and efficacy not established; no approved pediatric dosing.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Start at low end of dosing range (0.05 mg once daily); titrate slowly due to increased risk of hypotension and hallucinations.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
None.
None
May cause valvular heart disease; fibrotic complications (pleural, pericardial, peritoneal); sudden sleep onset; orthostatic hypotension; hallucinations; impulse control disorders; dopamine agonist withdrawal syndrome.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Hypersensitivity to pergolide; ergot alkaloid allergy; history of cardiac valvulopathy.
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
No specific food interactions documented. However, high-protein meals may reduce absorption; take consistently with or without food. Avoid alcohol due to additive CNS depression.
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
Pergolide (PERMAX) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but no adequate, well-controlled studies in pregnant women exist. First trimester: theoretical risk due to dopamine agonist activity; second/third trimester: limited data, risk of postpartum hemorrhage due to ergot alkaloid properties. Use only if benefit outweighs risk.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
Pergolide suppresses lactation by inhibiting prolactin secretion. It is excreted in human breast milk; M/P ratio not established. Contraindicated in breastfeeding women due to potential for dopamine receptor stimulation in infant and suppression of lactation.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
No specific dose adjustment guidelines for pregnancy. Pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce serum levels, but efficacy and safety data are lacking. Use lowest effective dose if unavoidable. Avoid postpartum due to lactation suppression effects.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Permax (pergolide) is a dopamine receptor agonist used for Parkinson's disease. Due to risk of valvular heart disease, it is withdrawn from the US market; use only in exceptional cases with echocardiogram monitoring. Titrate slowly to avoid orthostatic hypotension. May cause sudden sleep episodes; advise patients not to drive. Do not abruptly discontinue (risk of neuroleptic malignant syndrome).
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Take exactly as prescribed; do not stop suddenly without consulting doctor.,May cause dizziness, especially when standing up; rise slowly and avoid sudden position changes.,Can cause sudden sleepiness; do not drive or operate machinery until you know how the drug affects you.,Report any new or worsening heart palpitations, shortness of breath, or swelling in ankles/feet.,Avoid alcohol as it may increase dizziness and drowsiness.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERMAX vs FLEXERIL, answered by our medical review team.
PERMAX is a Dopamine Agonist that works by Dopamine D1/D2 receptor agonist; also activates α2-adrenergic and serotonin receptors, reducing prolactin secretion.. FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERMAX and FLEXERIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERMAX is: Initial: 0.05 mg orally once daily; titrate by 0.05-0.1 mg/day every 2-3 days; usual therapeutic dose: 0.1-0.5 mg three times daily; maximum: 1.5 mg three times daily.. The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERMAX and FLEXERIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERMAX is classified as Category C. Pergolide (PERMAX) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but no adequate, well-controlled studies in pregnant women ex. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.